Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodefici...( BOSTON and CARLSBAD Calif. Feb. 7...),Health

BOSTON and CARLSBAD, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that data was presented demonstrating the potent activity of the Company's non-nucleoside reverse transcriptase inhibitor (NNRTI) family of compounds against the human-immunodeficiency virus (HIV), the known causative agent of AIDS, including NNRTI-resistant strains.

The data was presented at the 15th Annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

The data showed that Ardea's lead NNRTI candidate, RDEA806, is a potent inhibitor of HIV, including the most common efavirenz resistant viruses. Oral dosing with RDEA806 achieves trough levels in humans that average at least 10-fold higher than the serum-adjusted EC50.

"This level of exposure over the concentration of drug needed to inhibit replication of the virus by 50% supports the potential for promising antiviral activity of our drug in HIV-infected patients who are naive to antiretroviral therapy," said Barry D. Quart, PharmD, Ardea's President and CEO. "NNRTIs are a critical component of current HIV therapy; however, there is an unmet need for safer, better tolerated NNRTIs that also work against viruses resistant to the most widely used NNRTIs."

The posters are available on the conference website (http://www.retroconference.org) and on the Company website (http://www.ardeabio.com) under the titles "An IQ Assessment of RDEA806, A Potent NNRTI with an Excellent Activity Profile in the Presence of Human Serum Proteins" and "RDEA427 and RDEA640 are Novel NNRTIs with Potent Anti-HIV Activity against NNRTI-Re
'/>"/>